Alnylam Pharmaceuticals Stock Price, News & Analysis
ALNY
NASDAQ
Company Description
Welcome to the overview page for Alnylam Pharmaceuticals (ALNY), where you can find comprehensive stock information and company updates.
Explore the latest news on strategic partnerships, quarterly and annual financial results, and regulatory filings including SEC reports and insider transactions.
Visualize performance trends using the interactive price chart, and keep track of upcoming events such as earnings calls, dividend dates, and investor conferences.
Stock Performance
Latest News
SEC Filings
Insider Radar
Net Sellers
90-Day Summary
0
Shares Bought
24,256
Shares Sold
22
Transactions
Most Recent Transaction
Fitzgerald Kevin Joseph
(CSO & EVP, Head of Research)
sold
129 shares
@ $451.51
on Nov 17, 2025
Based on SEC Form 4 filings over the last 90 days.
Financial Highlights
$2,248,243,000
Revenue (TTM)
-$278,157,000
Net Income (TTM)
-$2.18
-$8,312,000
Operating Cash Flow
-12.37%
-7.87%
Upcoming Events
JAN
12
January 12, 2026
Marketing
Company overview and Q&A
The Westin St. Francis, San Francisco; live audio webcast on investor events page; replay within 48 hours.
SEP
01
September 1, 2027 - December 31, 2027
Operations
siRELIS capabilities operational
Completion of Norton, MA expansion; full siRELIS production capabilities; capacity for clinical/commercial siRNA
SEP
15
September 15, 2028
Financial
Convertible notes maturity
Maturity of $575 million 0.00% convertible senior notes due 2028
Short Interest History
Last 12 Months
Loading short interest data...
Days to Cover History
Last 12 Months
Loading days to cover data...
Frequently Asked Questions
What is the current stock price of Alnylam Pharmaceuticals (ALNY)?
The current stock price of Alnylam Pharmaceuticals (ALNY) is $399.4 as of January 8, 2026.
What is the market cap of Alnylam Pharmaceuticals (ALNY)?
The market cap of Alnylam Pharmaceuticals (ALNY) is approximately 55.8B. Learn more about what market capitalization means .
What is the revenue (TTM) of Alnylam Pharmaceuticals (ALNY) stock?
The trailing twelve months (TTM) revenue of Alnylam Pharmaceuticals (ALNY) is $2,248,243,000.
What is the net income of Alnylam Pharmaceuticals (ALNY)?
The trailing twelve months (TTM) net income of Alnylam Pharmaceuticals (ALNY) is -$278,157,000.
What is the earnings per share (EPS) of Alnylam Pharmaceuticals (ALNY)?
The diluted earnings per share (EPS) of Alnylam Pharmaceuticals (ALNY) is -$2.18 on a trailing twelve months (TTM) basis. Learn more about EPS .
What is the operating cash flow of Alnylam Pharmaceuticals (ALNY)?
The operating cash flow of Alnylam Pharmaceuticals (ALNY) is -$8,312,000. Learn about cash flow.
What is the profit margin of Alnylam Pharmaceuticals (ALNY)?
The net profit margin of Alnylam Pharmaceuticals (ALNY) is -12.37%. Learn about profit margins.
What is the operating margin of Alnylam Pharmaceuticals (ALNY)?
The operating profit margin of Alnylam Pharmaceuticals (ALNY) is -7.87%. Learn about operating margins.
What is the gross margin of Alnylam Pharmaceuticals (ALNY)?
The gross profit margin of Alnylam Pharmaceuticals (ALNY) is 86.37%. Learn about gross margins.
What is the current ratio of Alnylam Pharmaceuticals (ALNY)?
The current ratio of Alnylam Pharmaceuticals (ALNY) is 2.78, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.
What is the gross profit of Alnylam Pharmaceuticals (ALNY)?
The gross profit of Alnylam Pharmaceuticals (ALNY) is $1,941,730,000 on a trailing twelve months (TTM) basis.
What is the operating income of Alnylam Pharmaceuticals (ALNY)?
The operating income of Alnylam Pharmaceuticals (ALNY) is -$176,885,000. Learn about operating income.